• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.

作者信息

Shimazaki C, Uchida R, Nakano S, Namura K, Fuchida S-i, Okano A, Okamoto M, Inaba T

出版信息

Leukemia. 2005 Jun;19(6):1102-3. doi: 10.1038/sj.leu.2403758.

DOI:10.1038/sj.leu.2403758
PMID:15830008
Abstract
摘要

相似文献

1
High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.
Leukemia. 2005 Jun;19(6):1102-3. doi: 10.1038/sj.leu.2403758.
2
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.硼替佐米可增加骨髓瘤患者的成骨细胞活性，无论其对治疗的反应如何。
Eur J Haematol. 2006 Sep;77(3):233-8. doi: 10.1111/j.1600-0609.2006.00692.x.
3
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.硼替佐米联合美法仑-泼尼松与美法仑-泼尼松在多发性骨髓瘤 III 期 VISTA 试验中的骨疾病事件减少、改善骨重塑和骨愈合证据。
Eur J Haematol. 2011 May;86(5):372-84. doi: 10.1111/j.1600-0609.2011.01599.x. Epub 2011 Mar 30.
4
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.硼替佐米作为一线治疗药物，能迅速刺激多发性骨髓瘤患者的成骨细胞活性和骨基质沉积，并能在体外刺激成骨细胞增殖和分化。
Eur J Haematol. 2010 Oct;85(4):290-9. doi: 10.1111/j.1600-0609.2010.01485.x. Epub 2010 Jul 22.
5
Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.骨扫描图像显示硼替佐米治疗多发性骨髓瘤患者后成骨细胞功能增强。
Eur J Haematol. 2011 Jan;86(1):83-6. doi: 10.1111/j.1600-0609.2010.01523.x. Epub 2010 Nov 11.
6
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.骨祖细胞分化不受免疫调节性沙利度胺类似物的影响，但低浓度硼替佐米可促进其分化，而这两种药物均可抑制破骨细胞分化。
Int J Oncol. 2008 Jul;33(1):129-36.
7
Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.硼替佐米联合传统化疗药物治疗多发性骨髓瘤与单独使用硼替佐米的比较。
Jpn J Clin Oncol. 2007 Dec;37(12):961-8. doi: 10.1093/jjco/hym126. Epub 2007 Dec 21.
8
[Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].硼替佐米与地塞米松联合治疗两名难治性多发性骨髓瘤患者的有效性
Rinsho Ketsueki. 2005 Apr;46(4):269-73.
9
Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.硼替佐米直接抑制多发性骨髓瘤中的破骨细胞功能：对骨髓瘤骨病管理的启示。
Leuk Res. 2008 Nov;32(11):1646-7. doi: 10.1016/j.leukres.2008.06.017. Epub 2008 Jul 9.
10
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.硼替佐米联合地塞米松治疗可诱导反应性多发性骨髓瘤患者的成骨细胞活化。
Int J Hematol. 2007 Aug;86(2):180-5. doi: 10.1532/IJH97.07030.

引用本文的文献

1
PfAgo-based dual signal amplification biosensor for rapid and highly sensitive detection of alkaline phosphatase activity.基于 PfAgo 的双信号放大生物传感器用于快速和高灵敏检测碱性磷酸酶活性。
Mikrochim Acta. 2024 Jul 2;191(7):439. doi: 10.1007/s00604-024-06516-9.
2
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications.多发性骨髓瘤中的骨骼疾病：生物学和临床意义。
Cells. 2022 Jul 27;11(15):2308. doi: 10.3390/cells11152308.
3
Bortezomib Rescues Ovariectomy-Induced Bone Loss via SMURF-Mediated Ubiquitination Pathway.硼替佐米通过 SMURF 介导的泛素化通路挽救卵巢切除诱导的骨丢失。
Oxid Med Cell Longev. 2021 Dec 31;2021:9661200. doi: 10.1155/2021/9661200. eCollection 2021.
4
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.硼替佐米及新型蛋白酶体抑制剂对骨髓瘤细胞和骨微环境的作用机制：对骨髓瘤诱导的骨重塑改变的影响
Biomed Res Int. 2015;2015:172458. doi: 10.1155/2015/172458. Epub 2015 Oct 22.
5
Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.接受不同治疗方案的多发性骨髓瘤患者的骨特异性碱性磷酸酶水平
Turk J Haematol. 2014 Dec 5;31(4):374-80. doi: 10.4274/tjh.2013.0004.
6
Proteasome inhibitors and bone disease.蛋白酶体抑制剂与骨病。
Semin Hematol. 2012 Jul;49(3):243-8. doi: 10.1053/j.seminhematol.2012.04.011.
7
Soluble molecules and bone metabolism in multiple myeloma: a review.多发性骨髓瘤中的可溶性分子与骨代谢：综述
Clin Cases Miner Bone Metab. 2008 Jan;5(1):67-70.
8
Targeting bone as a therapy for myeloma.将骨骼作为骨髓瘤的一种治疗靶点。
Cancer Microenviron. 2011 Dec;4(3):299-311. doi: 10.1007/s12307-011-0079-2. Epub 2011 Aug 11.
9
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.一种蛋白酶体抑制剂硼替佐米通过下调转移基因抑制乳腺癌生长并减少溶骨性。
Clin Cancer Res. 2010 Oct 15;16(20):4978-89. doi: 10.1158/1078-0432.CCR-09-3293. Epub 2010 Sep 15.
10
Tumor-host cell interactions in the bone disease of myeloma.骨髓瘤骨病中的肿瘤-宿主细胞相互作用。
Bone. 2011 Jan;48(1):121-8. doi: 10.1016/j.bone.2010.06.029. Epub 2010 Jul 13.